Want to see HK:2561 full AI Analyst Report?
2561 Stock Chart & Stats
HK$33.68
--
Market closed
HK$33.68
--
Day’s Range― - ―
52-Week RangeHK$18.50 - HK$52.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)37.57K
Market Cap
HK$2.15B
Enterprise ValueHK$1.39B
Total Cash (Recent Filing)HK$632.64M
Total Debt (Recent Filing)HK$176.99M
Price to Earnings (P/E)―
Beta0.93
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding113,926,865
10 Day Avg. Volume36,930
30 Day Avg. Volume37,566
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)4.01
Price to Sales (P/S)19001.90
P/FCF Ratio-6.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet FlexibilityModest leverage and historically very low debt (2022–2024) provide structural financial flexibility. This reduces near-term solvency risk, giving management time to execute clinical programs or seek non-dilutive funding, supporting the firm’s ability to pursue long-term value-creating milestones.
Positive Gross ProfitPositive gross profit indicates underlying product or program-level economics that can support margins once operating costs are controlled. Sustained positive gross margins are a durable foundation for future operating leverage and eventual profitability if SG&A/R&D growth is managed.
Sustained Investment In Growth/R&DConsistent high investment suggests ongoing R&D or development spending to build a product pipeline. For a specialty drug developer, this creates a structural runway for future revenue streams and value creation if programs progress, making current losses an investment rather than mere decline.
Bears Say
Revenue Decline And Persistent LossesA sharp revenue decline alongside recurring negative EBIT and net income signals weak demand or commercialization setbacks. Over the medium term, shrinking top-line undermines scalability and worsens operating leverage, reducing the company's ability to self-fund development or sustain growth initiatives.
Structural Cash BurnPersistent negative operating and free cash flow, and worsening cash burn in 2025, create a durable funding need. This raises reliance on external capital, increases dilution or refinancing risk, and constrains strategic options unless cash generation meaningfully improves.
Rising Debt Increases Funding RiskAn increase in total debt in 2025 reduces financial headroom and raises refinancing and interest burden risks. Combined with ongoing losses, higher leverage materially increases the probability the company will need dilutive or costly financing over the medium term, pressuring long-term flexibility.
VISEN Pharmaceuticals News
2561 FAQ
What was VISEN Pharmaceuticals’s price range in the past 12 months?
VISEN Pharmaceuticals lowest stock price was HK$18.50 and its highest was HK$52.90 in the past 12 months.
What is VISEN Pharmaceuticals’s market cap?
VISEN Pharmaceuticals’s market cap is HK$2.15B.
When is VISEN Pharmaceuticals’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were VISEN Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is VISEN Pharmaceuticals overvalued?
According to Wall Street analysts VISEN Pharmaceuticals’s price is currently Overvalued.
Does VISEN Pharmaceuticals pay dividends?
VISEN Pharmaceuticals does not currently pay dividends.
What is VISEN Pharmaceuticals’s EPS estimate?
VISEN Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VISEN Pharmaceuticals have?
VISEN Pharmaceuticals has 113,926,865 shares outstanding.
What happened to VISEN Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VISEN Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2561
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VISEN Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Company Description
VISEN Pharmaceuticals
VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Technical Analysis
HUTCHMED (China)
―
Hua Medicine
―
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
CanSino Biologics, Inc. Class H
―